Effects of platelet-activating factor antagonist CV-3988 in preservation of heart and lung for transplantation

The Design and Analysis of Clinical Experiments.

Michael Hills, Joseph L. Fleiss · Journal of the Royal Statistical Society Series A (General) · 1987 · 3.3K citations

Public Health, Biostatistics, Pharmacology +11

Inhibition of the iron-catalysed formation of hydroxyl radicals from superoxide and of lipid peroxidation by desferrioxamine

John M.C. Gutteridge, Ramsay Richmond, Barry Halliwell · Biochemical Journal · 1979 · 631 citations · Full text

Life Sciences, Biochemistry, Pharmacology +15

Activation of human neutrophils with 1-<i>O</i>-hexadecyl/octadecyl-2-acetyl-<i>sn</i>-glycerol-3-phosphorylcholine (platelet activating factor).

James O. Shaw, R. Neal Pinckard, K S Ferrigni et al. · The Journal of Immunology · 1981 · 385 citations

Life Sciences, Cell Biology, Immunology +11

Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.

Philip E. Hallaway, John W. Eaton, S. Scott Panter et al. · Proceedings of the National Academy of Sciences · 1989 · 189 citations · Full text

Medicine, Pharmacology, Toxicology +17

Involvement of hydrogen peroxide and hydroxyl radical in the ‘oxygen paradox’: Reduction of creatine kinase release by catalase, allopurinol or deferoxamine, but not by superoxide dismutase**

Charles E. Myers, Steven J. Weiss, M. M. Kirsh et al. · Journal of Molecular and Cellular Cardiology · 1985 · 168 citations

Life Sciences, Biochemistry, Physiology +16